Moderna Stock Is Soaring. Is It Too Late to Buy?
Yahoo Finance ·
Moderna 's ( MRNA +2.56% ) share price has more than doubled this year as the market has grown increasingly optimistic about the company's pipeline and encouraging regulatory progress for its flu vaccine. But after such a sharp rally, it's fair to ask whether there's still an opportunity here to make some money. The investment case for Moderna isn't just about COVID-19 vaccines anymore. It's about what comes next. Today, the company has three commercial products, multiple late-stage vaccine programs, and an expanding pipeline that stretches well beyond infectious diseases. Moderna is developing personalized cancer vaccines in partnership with Merck and pursuing therapies for rare genetic disorders. The company is now preparing for multiple product launches in 2027 and 2028, including seasonal flu, a flu/COVID-19 combination vaccine, and a norovirus vaccine. That's a dramatically different company than the one investors knew during the pandemic, when nearly all of its revenue came from a single COVID-19 vaccine. If even a handful of these late-stage programs reach the market, Moderna could become a much more diversified biotechnology company with multiple sources of recurring revenue. And the financial picture is improving, too.
DYAX Investor Sentiment
Bullish (Long) 49% · Bearish (Short) 51%
318 participants
Related News
- Top energy stocks entering Q2 earnings season, ranked by EPS revisions
- Compass gains on new late-stage trial data for psychedelic therapy in depression
- onsemi to divest two manufacturing sites
- Lightworks, Scotiabank, Sun Life, and Telus launch AI consortium
- Whering to expand AI wardrobe tools with $7m in eBay, Google AI backing
- Dorchester Minerals to buy Williston Basin royalty interests